This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Methoxetamine: Difference between revisions
>Kenan |
>Kenan |
||
| Line 22: | Line 22: | ||
==Pharmacology== | ==Pharmacology== | ||
{{Main|NMDA receptor antagonist}} | {{Main|NMDA receptor antagonist}} | ||
MXE acts as a noncompetitive [[NMDA receptor antagonist]] and [[serotonin]]-[[Reuptake Inhibitor|reuptake inhibitor]].<ref name="MXE Binding Profile">[http://www.homeoffice.gov.uk/publications/agencies-public-bodies/acmd1/methoxetamine2012?view=Binary "ACMD Methoxetamine Report (2012)"]. Advisory Council on the Misuse of Drugs. October 2012. pp. 14–15. Retrieved 6 February 2013.</ref> NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. Dissociatives close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually an almost identical equivalent of the famous “[http://en.wikipedia.org/wiki/K-hole k-hole]. | MXE acts as a noncompetitive [[NMDA receptor antagonist]] and [[serotonin]]-[[Reuptake Inhibitor|reuptake inhibitor]].<ref name="MXE Binding Profile">[http://www.homeoffice.gov.uk/publications/agencies-public-bodies/acmd1/methoxetamine2012?view=Binary "ACMD Methoxetamine Report (2012)"]. Advisory Council on the Misuse of Drugs. October 2012. pp. 14–15. Retrieved 6 February 2013.</ref> NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. Dissociatives close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually an almost identical equivalent of the famous “[http://en.wikipedia.org/wiki/K-hole k-hole]”. MXE was reported to be similar to [[Ketamine|ketamine]] <ref>Kjellgren, A., & Jonsson, K. (2013). Methoxetamine (MXE)--a phenomenological study of experiences induced by a {\dq}legal high{\dq} from the internet. Journal of Psychoactive Drugs, 45(3), 276–286. https://doi.org/\url{10.1080/02791072.2013.803647}</ref>, despite being stronger and having a longer duration. <ref>Coppola, M., & Mondola, R. (2012). Methoxetamine: From drug of abuse to rapid-acting antidepressant. Medical Hypotheses, 79(4), 504–507. https://doi.org/10.1016/j.mehy.2012.07.002</ref> | ||
Because of its structural similarity to [[3-OH-PCP]], it was falsely believed to carry [[opioid]] properties.<ref>Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis. https://doi.org/10.1002/dta.1620</ref> This claim cannot be supported by actual data, instead showing only insignificant affinity for the µ-opioid receptor by the substance itself, although in-vivo metabolites could yield different effects.<ref name="MXE Binding Profile"/> | Because of its structural similarity to [[3-OH-PCP]], it was falsely believed to carry [[opioid]] properties.<ref>Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis. https://doi.org/10.1002/dta.1620</ref> This claim cannot be supported by actual data, instead showing only insignificant affinity for the µ-opioid receptor by the substance itself, although in-vivo metabolites could yield different effects.<ref name="MXE Binding Profile"/> | ||